These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 1279258

  • 1. [Adjuvant chemotherapy with MVP-CAB (methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin and bleomycin) for epithelial tumors of the upper urinary tract].
    Fujii A, Oka N, Murata Y, Higuchi A, Itoh N, Ishikawa J, Tanaka H.
    Nihon Hinyokika Gakkai Zasshi; 1992 Oct; 83(10):1609-14. PubMed ID: 1279258
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 3. [Adjuvant chemotherapy (MVP-CAB; methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin, and bleomycin) for bladder cancer].
    Fujii A, Oka N, Murata Y, Higuchi A, Itoh N, Nakagawa J, Tanaka H, Izumi T, Yamada Y.
    Nihon Hinyokika Gakkai Zasshi; 1992 May; 83(5):619-26. PubMed ID: 1379656
    [Abstract] [Full Text] [Related]

  • 4. [Combination chemotherapy with methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin, and bleomycin (MVP-CAB) for metastatic urothelial cancer].
    Fujii A, Oka N, Miyasaki S, Higuchi A, Itoh N, Okamoto Y, Tanaka H, Hiro-oka K, Shimatani N, Inoue T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Jun; 82(6):932-9. PubMed ID: 1715415
    [Abstract] [Full Text] [Related]

  • 5. [A study of the use of methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, bleomycin (MVP-CAB) in metastatic transitional cell carcinoma].
    Fujii A, Den S, Nakamura I, Ohshima H, Nagata H, Izumi T, Takechi Y, Kawaida T, Kamidono S, Yasuno H.
    Hinyokika Kiyo; 1987 May; 33(5):697-703. PubMed ID: 2444083
    [Abstract] [Full Text] [Related]

  • 6. [Combination chemotherapy with methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, and bleomycin: MVP-CAB for disseminated urological cancer].
    Fujii A, Morishita S, Nakamura I, Oka Y, Ohshima H, Nagata H, Iwamoto T, Itoh N, Nakagawa Y, Miyazaki S.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan 20; 25(1):55-62. PubMed ID: 1691254
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up results of a Pilot Phase II study of multidrug chemotherapy (MVP-CAB) in patients with advanced urothelial cancer.
    Gohji K, Ono Y, Takenaka A, Nomi M, Okamoto M, Yuen K, Fujii A.
    Jpn J Clin Oncol; 1999 Apr 20; 29(4):204-8. PubMed ID: 10340044
    [Abstract] [Full Text] [Related]

  • 8. [Combination chemotherapy with methotrexate (MTX), vincristine (VCR), cisplatinum (CDDP), cyclophosphamide (CPM), adriamycin (ADM), and bleomycin (BLM); MVP-CAB in patients with advanced urothelial tract cancer].
    Fujii A, Morishita S, Nakamura I, Oka Y, Ohshima H, Nagata H, Iwamoto T, Izumi T, Miyasaki Z, Ito N.
    Nihon Hinyokika Gakkai Zasshi; 1988 Jun 20; 79(6):985-93. PubMed ID: 2460657
    [No Abstract] [Full Text] [Related]

  • 9. [Case report of a patient with advanced pelvic and ureteral cancer whose primary lesion could be enucleated after cytoreduction by modified CAP regimen].
    Mikata N, Imao S, Katoh A, Horiuti D, Tanaka Y, Sasaki H, Hamasima T.
    Gan No Rinsho; 1989 Dec 20; 35(15):1807-11. PubMed ID: 2481751
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
    Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W.
    J Urol; 2004 Oct 20; 172(4 Pt 1):1271-5. PubMed ID: 15371822
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH, Hsieh RK, Chiou TJ, Chen KK, Chang LS, Chen PM.
    J Urol; 1996 Jan 20; 155(1):118-21. PubMed ID: 7490806
    [Abstract] [Full Text] [Related]

  • 12. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
    Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M.
    J Urol; 2015 Apr 20; 193(4):1122-8. PubMed ID: 25444957
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.
    Kotake T, Usami M, Miki T, Kuroda M, Obata K, Osafune M, Fujioka H, Takasugi Y.
    Cancer Chemother Pharmacol; 1983 Apr 20; 11 Suppl():S38-42. PubMed ID: 6685580
    [Abstract] [Full Text] [Related]

  • 14. [A case of bilateral renal metastases from non Hodgkin's malignant lymphoma].
    Fujii A, Morishita S, Nakamura I, Oka Y, Kimura S, Hirata Y, Sashikata T, Fujiwara T, Den S.
    Nihon Gan Chiryo Gakkai Shi; 1989 Oct 20; 24(10):2441-6. PubMed ID: 2614183
    [Abstract] [Full Text] [Related]

  • 15. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
    Igawa M, Ueki T, Ueda M, Okada K, Usui T, Ohnishi Y, Kume T, Masu C, Ishino T, Nakatsu H.
    Gan To Kagaku Ryoho; 1989 Aug 20; 16(8 Pt 1):2577-82. PubMed ID: 2673046
    [Abstract] [Full Text] [Related]

  • 16. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
    Yamauchi T, Hida S, Ooishi K, Okada K, Yoshida O.
    Hinyokika Kiyo; 1985 Jul 20; 31(7):1093-104. PubMed ID: 2414981
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N, Arima K, Sugimura Y.
    Int J Urol; 2008 Sep 20; 15(9):800-3. PubMed ID: 18651862
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results.
    Kuroiwa T, Naito S, Hasuo K, Kishikawa T, Masuda K, Kumazawa J.
    Cancer Chemother Pharmacol; 1995 Sep 20; 35(5):357-63. PubMed ID: 7850915
    [Abstract] [Full Text] [Related]

  • 19. [Combination chemotherapy of advanced transitional cell carcinoma with cis-platinum, cyclophosphamide, adriamycin and 5-fluorouracil (CISCAF)].
    Fujioka H, Tada Y, Nakano E, Matsuda M, Osafune M, Sagawa S, Takaha M, Sonoda T.
    Gan To Kagaku Ryoho; 1984 Aug 20; 11(8):1612-6. PubMed ID: 6541019
    [Abstract] [Full Text] [Related]

  • 20. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II) and adriamycin in urothelial cancer].
    Konami T, Wakabayashi Y, Kim T, Ishida A, Arai Y, Konishi T, Pak K, Takeuchi H, Tomoyoshi T, Watanabe J.
    Hinyokika Kiyo; 1989 Feb 20; 35(2):231-7. PubMed ID: 2472048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.